These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 23834118)

  • 1. Alemtuzumab and chronic plaque psoriasis.
    Aslam A; Marsland AM; Rog D; Griffiths CE
    Br J Dermatol; 2013 Jul; 169(1):184-6. PubMed ID: 23834118
    [No Abstract]   [Full Text] [Related]  

  • 2. Eosinophilia during psoriasis treatment with TNF antagonists.
    Malisiewicz B; Murer C; Pachlopnik Schmid J; French LE; Schmid-Grendelmeier P; Navarini AA
    Dermatology; 2011; 223(4):311-5. PubMed ID: 22301393
    [No Abstract]   [Full Text] [Related]  

  • 3. Resident Rounds. Part III A. Serendipitous improvement in moderate to severe acne in psoriasis patients treated with ustekinumab: a two-case series.
    Jensen JD; Huynh T; Cafardi J; Sami N
    J Drugs Dermatol; 2013 Jun; 12(6):710-1. PubMed ID: 23839194
    [No Abstract]   [Full Text] [Related]  

  • 4. Ustekinumab in severe complicated erythrodermic psoriasis: rapid clearing, safety, and sustained remission.
    Koutsoukou XA; Papadavid E; Theodoropoulos K; Rigopoulos D
    Dermatol Ther; 2014; 27(5):257-9. PubMed ID: 24813816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Good efficacy and tolerability of ustekinumab in a patient with severe psoriasis under haemodialysis.
    Larquey M; Poreaux C; Cuny JF; Barbaud A; Schmutz JL
    Eur J Dermatol; 2014; 24(5):618-9. PubMed ID: 25445092
    [No Abstract]   [Full Text] [Related]  

  • 6. Extensive plaque psoriasis successfully treated with adalimumab (Humira).
    Sladden MJ; Mortimer NJ; Hutchinson PE
    Br J Dermatol; 2005 May; 152(5):1091-2. PubMed ID: 15888191
    [No Abstract]   [Full Text] [Related]  

  • 7. A scientific debate: key clinical questions in the management of psoriasis.
    Stingl G
    J Eur Acad Dermatol Venereol; 2012 Aug; 26 Suppl 5():1. PubMed ID: 22758910
    [No Abstract]   [Full Text] [Related]  

  • 8. Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis.
    Leman J; Burden AD
    Br J Dermatol; 2012 Nov; 167 Suppl 3():12-20. PubMed ID: 23082811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Review of Ixekizumab, an Anti-Interleukin-17A Monoclonal Antibody, for Moderate-to-Severe Plaque Psoriasis.
    Peranteau AJ; Turkeltaub AE; Tong Y; Nawas Z; Tyring SK
    Skin Therapy Lett; 2016 Nov; 21(6):1-6. PubMed ID: 27825174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Marked improvement in nail psoriasis during treatment with adalimumab.
    Irla N; Yawalkar N
    Dermatology; 2009; 219(4):353-6. PubMed ID: 19851059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secukinumab survival and long-term efficacy in patients with plaque psoriasis: real-life data from a tertiary hospital in Greece.
    Sotiriou E; Tsentemeidou A; Vakirlis E; Sideris N; Ioannides D
    J Eur Acad Dermatol Venereol; 2019 Feb; 33(2):e82-e84. PubMed ID: 30176180
    [No Abstract]   [Full Text] [Related]  

  • 12. Topical treatment habits in psoriasis patients receiving adalimumab.
    Kolios AG; Rusca F; Reisenbauer K; Cozzio A; French LE; Navarini AA
    Dermatology; 2012; 224(3):228-30. PubMed ID: 22414626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful Use of Secukinumab in Various Scenarios of Psoriasis.
    Chhabra G; Verma P; Khunger N
    Skinmed; 2020; 18(5):274-276. PubMed ID: 33160436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erythrodermic psoriasis.
    Mumoli N; Vitale J; Gambaccini L; Sabatini S; Brondi B; Cei M
    QJM; 2014 Apr; 107(4):315. PubMed ID: 23764512
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical outcomes in patients on secukinumab (Cosentyx
    Sears AV; Szlumper C; Liu KW; Smith CH; Barker JNWN; Pink AE
    J Eur Acad Dermatol Venereol; 2019 Feb; 33(2):e89-e91. PubMed ID: 30198598
    [No Abstract]   [Full Text] [Related]  

  • 16. Adalimumab treatment for severe recalcitrant chronic plaque psoriasis.
    Ryan C; Kirby B; Collins P; Rogers S
    Clin Exp Dermatol; 2009 Oct; 34(7):784-8. PubMed ID: 19438535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case presentation of moderate-severe psoriasis.
    Salmhofer W
    J Eur Acad Dermatol Venereol; 2012 Aug; 26 Suppl 5():19-20. PubMed ID: 22758914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ustekinumab improves psoriasis-related gene expression in noninvolved psoriatic skin without inhibition of the antimicrobial response.
    Baerveldt EM; Onderdijk AJ; Kurek D; Kant M; Florencia EF; Ijpma AS; van der Spek PJ; Bastiaans J; Jansen PA; van Kilsdonk JW; Laman JD; Prens EP
    Br J Dermatol; 2013 May; 168(5):990-8. PubMed ID: 23278632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recalcitrant psoriasis responding to new bilogic drug: ustekinumab.
    Husein-ElAhmed H; Molina-Leyva A; Garrido-TorresPuchol V; Ruiz-Carrascosa J
    Ann Saudi Med; 2013; 33(6):632-3. PubMed ID: 24413873
    [No Abstract]   [Full Text] [Related]  

  • 20. Ustekinumab treats psoriasis refractory to seven conventional and biologic therapies.
    Rallis E; Verros CD
    Dermatol Online J; 2011 Apr; 17(4):14. PubMed ID: 21549089
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.